Supernus Pharmaceuticals, Inc. (SUPN) — Fair Value Analysis

Base-case fair value (P50): $48.67 · Current price: $51.53 · Verdict: Fairly Valued

The Verdict on SUPN

Based on our Monte Carlo simulations, SUPERNUS PHARMACEUTICALS INC (SUPN) is currently assessed as Fairly Valued. The analysis indicates a median fair value (P50) of $48.67, which represents a -5.6% difference compared to its current trading price of $51.53. While the current price is slightly above the P50, the magnitude of this difference positions SUPN within a range typically considered fair given market dynamics and a comprehensive view of potential future scenarios.

How SUPN stacks up against peers

SUPN's operational and financial health against its sector peers is rated as "average." This quality tier suggests that while the company maintains a stable footing, it does not exhibit significant competitive advantages or disadvantages that would dramatically alter its valuation trajectory beyond what the Monte Carlo simulations have already captured. The fair value assessment, indicating a -5.6% gap from the current $51.53 to the $48.67 median fair value, reflects this average standing.

What this means for investors

The Monte Carlo simulations suggest that SUPN is Fairly Valued, with the current price of $51.53 sitting just -5.6% above the median fair value of $48.67. This narrow differential implies that the market is largely pricing in SUPN's fundamentals and future prospects as modeled. While there's a slight premium to the P50, our FairCurve analysis concludes that the stock is appropriately valued. For a complete understanding of potential downside and upside scenarios, including the full bear-case and bull-case distribution, sign up for FairCurve to track SUPN's fair value as new fundamentals are released.